PABPC4

Across TCGA pan-cancer cohorts, PABPC4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PABPC4 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PABPC4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PABPC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, ESCA, and GBM are the cancer types where PABPC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	20	view →
ESCA	DFS	Median	II,III,IV	0.188	0.528	.006	12	view →
GBM	OS	Median	All	0.166	0.418	.022	6	view →
HNSC	OS	Median	IV	0.211	0.735	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.488	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PABPC4–LUAD (DFS)

Open the LUAD breakdown →